NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer

Exclusion Criteria

• •contraindication for Whipple procedure
• •an infiltration \>180° of the portal vein
• •abutment of the tumor to the superior mesenteric artery
• •infiltration of the superior mesenteric artery or the celiac trunk
• •chronic neuropathy \> grade 2
• •WHO performance score \>2
• •uncorrectable cholestasis (bilirubin \> 100mmol/l despite drainage attempts for more than four weeks prior to inclusion)
• •female patients in child bearing age not using adequate contraception (oral or subcutaneous contraceptives, intrauterine pessars (IUP), condoms)
• •pregnant or lactating women
• •mental or organic disorders which could interfere with giving informed consent or receiving treatments
• •Second malignancy diagnosed within the past 5 years, except non-melanomatous skin cancer or non-invasive cervical cancer
• •percutaneous biopsy of the primary tumor